News

Stay up to date on our
latest news and announcements.

News

Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

05/06/2023

Cytovation appoints Iman Barilero as Chief Development Officer

12/04/2023

Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors

17/02/2023

Cytovation presents Phase I dose escalation results at ESMO

28/10/2022

Cytovation collaborates with Recurrent Respiratory Papillomatosis Foundation to expand its clinical investigations of CyPep-1 into rare neoplastic disease

08/02/2022

Cytovation raises $20 million in Series A financing round to advance clinical development of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

26/01/2022

CyPep-1 Shows Preliminary Safety, Tolerability and Early Signs of Efficacy in Part 1 of its Ph I/IIa CICILIA Trial Which Now Moves to Expansion Phase

25/09/2021

Cytovation Announces Clinical Collaboration with MSD to Evaluate its First-in-class Tumorolytic Agent CyPep-1 in Combination with KEYTRUDA

30/06/2021

Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers

29/05/2020

Cytovation and SMS-oncology sign agreement on conduct of phase I/II trial with CyPep-1 in solid tumors

08/08/2019

© 2022 Cytovation ASA | All Rights Reserved
Webdesign by Limedrop

Terms & Conditions | Privacy & Cookies | Code of Ethics

© 2022 Cytovation ASA | All Rights Reserved | Webdesign by Limedrop
Terms & Conditions | Privacy & Cookies | Code of Ethics